Clinical and pathological characteristics of the 221 patients
| Clinical characteristic | Overall cohort n=221 |
| Age, median (range) | 70 (42–92) |
| Sex | |
| Male | 100 (45.2) |
| Female | 121 (54.8) |
| Smoking status | |
| Current/former | 212 (95.9) |
| Never | 9 (4.1) |
| ECOG PS | |
| PS 0–1 | 173 (79.4) |
| PS 2 | 45 (20.6) |
| N.A. | 3 |
| Histology | |
| Adenocarcinoma | 177 (80.1) |
| Squamous | 23 (10.4) |
| NSCLC NOS | 21 (9.5) |
| Oncogene driver | |
| KRAS | 80 (39.2) |
| BRAF | 14 (6.9) |
| Other drivers* | 19 (9.3) |
| None identified | 91 (44.6) |
| None assessed | 17 |
| Allbumin | |
| ≥3.5 g/dL | 159 (76.4) |
| <3.5 g/dL | 49 (23.6) |
| N.A. | 13 |
| PD-L1 expression | |
| ≥90% | 100 (45.2) |
| 50%–89% | 121 (54.8) |
| dNLR level | |
| Median (range) | 2.5 (0.87–13.31) |
| Blood draw (CBC) | |
| Same day of infusion | 192 (86.9) |
| 1–30 days before infusion | 29 (13.1) |
*Other drivers HER2, MET, and RET
CBC, complete blood count; dNLR, derived neutrophil-to-lymphocyte ratio; ECOG PS, Eastern Cooperative Oncology Group Performance Status; N.A, not available; NSCLC NOS, non-small cell lung cancer not otherwise specified; PD-L1, programmed cell death ligand 1.